Fredrik Sund

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 300 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Cytomegalovirus‐Specific <scp>CD</scp>4 and <scp>CD</scp>8 <scp>T</scp> Cell Responses in Infants and Children

A-K Lidehäll, Mona‐Lisa Engman, Fredrik Sund et al. · Scandinavian Journal of Immunology · 2012 · 45 citations

Life Sciences, Immunology, Infectious Diseases +17

Comparison of a Duplex Quantitative Real-Time PCR Assay and the COBAS Amplicor CMV Monitor Test for Detection of Cytomegalovirus

Björn Herrmann, Viviana Cavaglia Larsson, Carl‐Johan Rubin et al. · Journal of Clinical Microbiology · 2004 · 45 citations · Full text

Medicine, Infectious Diseases, Microbiology +17

Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis

Gabriel Westman, Elisabeth Aurelius, Clas Ahlm et al. · Clinical Microbiology and Infection · 2020 · 45 citations · Full text

Life Sciences, Neurology, Neuroscience +17

CMV‐specific T‐cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study

Fredrik Sund, Anna‐Karin Lidehäll, Kerstin Claesson et al. · Clinical Transplantation · 2009 · 44 citations

Life Sciences, Immunology, Infectious Diseases +17